Control and lot release of meningococcal group C conjugate vaccines.
Meningococcal group C conjugate vaccines were first introduced to the UK in 1999. To date, the vaccines have been demonstrated to have an efficacy of approximately 90% and have since been adopted by other countries worldwide. The development of control tests used for lot release of meningococcal group C vaccines has been based on those used for Haemophilus influenzae type b conjugates, the key criteria being measurement of free saccharide and conjugate integrity by physicochemical means. In future, meningococcal group C vaccines are likely to be replaced by multivalent formulations containing different components in combination. This will present a new challenge for regulatory authorities and more extensive testing will be required to ensure vaccine safety and efficacy.
Suker
Janet
J
National Institute for Biological Standards and Control, South Mimms Potters Bar, UK. jsuker@nibsc.ac.uk
Feavers
Ian M
IM
Corbel
Michael J
MJ
Jones
Christopher
C
Bolgiano
Barbara
B
D017607:Aluminum Compounds / Q000737:chemistry; D000818:Animals; D004355:Drug Stability; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D022401:Meningococcal Vaccines / Q000737:chemistry* / Q000276:immunology; D038542:Neisseria meningitidis, Serogroup C; D011135:Polysaccharides, Bacterial / Q000032:analysis*; D011786:Quality Control; D018074:Vaccines, Conjugate / Q000737:chemistry / Q000276:immunology
D017607:Aluminum Compounds; D022401:Meningococcal Vaccines; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate; C037676:meningococcal group C polysaccharide; C410218:serogroup C meningococcal conjugate vaccine